搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
The Pharma Letter
4 天
Patritumab deruxtecan closer to market
The HERTHENA-Lung02 Phase III trial of patritumab deruxtecan in advanced EGFR-mutated NSCLC patients who received prior EGFR ...
pharmaphorum
4 天
After FDA no, MSD/Daiichi post new data with lung cancer ADC
The result is a welcome endorsement of patritumab derxutecan's potential after the HER3-directed antibody-drug conjugate (ADC ...
BioSpace
5 天
Merck, Daiichi Score Late-Stage NSCLC Win for ADC, Flag Two Deaths
Despite meeting the primary endpoint in a Phase III study, two patients treated with Merck and Daiichi Sankyo’s experimental ...
4 天
潜在“first-in-class”ADC达3期试验主要终点,全球监管对话即将开展
HERTHENA-Lung02是一项全球性、多中心、开放标签的3期试验,共招募了586例患者,旨在评估每三周一次5.6mg/kg patritumab deruxtecan与四个周期的培美曲塞和铂类化疗相比,在转移性或局部晚期NSCLC患者中的疗效和安全性,这些患者携带EGFR激活突变(外显子19缺失或L858R)并接受过第三代EGFR ...
来自MSN
3 天
Study: Merck and Daiichi's Lung Cancer Treatment Shows Promise
Merck MRK announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC ...
GlobalData on MSN
4 天
Daiichi Sankyo and MSD’s ADC improves progression-free survival in NSCLC trial
Daiichi Sankyo and MSD (Merck & Co) have reported that the Phase III HERTHENA-Lung02 clinical trial of patritumab deruxtecan, ...
4 天
Daiichi Sankyo: Showing No Signs Of Slowing Down ADC Dominance
ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.
5 天
on MSN
Merck, Daiichi post late-stage trial win for novel lung cancer therapy
Merck (MRK) and Daiichi Sankyo's (DSNKY) lung cancer drug, patritumab deruxtecan hits the primary endpoint in a Phase 3 trial ...
5 天
Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study
Merck reported topline data from its HERTHENA-Lung02 phase 3 trial of patritumab deruxtecan in EGFR-mutated non-small cell ...
FierceBiotech
5 天
Merck, Daiichi rack up phase 3 ADC lung cancer win but report 2 deaths, immature OS data
A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, ...
Business Wire
5 天
Patritumab Deruxtecan Demonstrated Statistically Significant Improvement in Progression ...
BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)--The HERTHENA-Lung02 phase 3 trial evaluating patritumab deruxtecan in patients with locally advanced or metastatic EGFR-mutated non-small cell ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果
反馈